Comparative Pharmacology
Head-to-head clinical analysis: DEPOCYT versus TECVAYLI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPOCYT versus TECVAYLI.
DEPOCYT vs TECVAYLI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cytarabine is a nucleoside analog that inhibits DNA polymerase, leading to termination of DNA chain elongation and cell death in the S phase of the cell cycle.
Bispecific T-cell engager antibody that binds to BCMA on multiple myeloma cells and CD3 on T-cells, leading to T-cell activation and targeted cytotoxicity.
50 mg intrathecally via lumbar puncture or intraventricularly via Ommaya reservoir on days 1, 15, 29, 43, 57, 71, 85, and 99 for induction; followed by consolidation and maintenance doses. Administer with dexamethasone 4 mg PO/IV twice daily for 5 days starting on the day of DepoCyt injection.
Subcutaneous injection: Step-up dosing schedule. First dose 0.06 mg/kg, then 0.3 mg/kg on day 4, followed by 1.5 mg/kg weekly starting day 7. Maximum single dose 1.5 mg/kg.
None Documented
None Documented
After intrathecal administration, the terminal half-life of cytarabine in CSF is 2.5-4.5 hours (mean 3.5 hours) due to slow clearance from CSF; systemic half-life is 10-15 minutes due to rapid deamination.
22.5 days (range 10–35 days) based on population pharmacokinetic analysis; supports every-2-week dosing after step-up.
Renal excretion of cytarabine metabolites accounts for >70% of elimination; unchanged cytarabine excretion is minimal (<10%). Biliary/fecal excretion is negligible (<5%).
Primarily catabolized to small peptides and amino acids; not expected to be excreted renally or hepatically to a significant extent.
Category C
Category C
Antineoplastic
Antineoplastic